



2022

Financial Report

GAMIAN-Europe




GAMIAN-Europe

The voice of patients in mental health


www.gamian.eu

Operating Income



€53.697,3 accrued to 2023 for continued projects

Operating charges



Industry		
Company	Funding	Percentage of Funding
Janssens Pharmaceutica	125.246,00	27,46%
Boehringer Ingelheim International GmbH	51.000,00	11,18%
Teva Branded Pharmaceutical Products R&D Inc	45.000,00	9,87%
Novartis Pharma AG	36.218,00	7,92%
Servier Affaires Medicales	28.200,00	6,18%
Angelini Pharma S.p.A	25.000,00	5,48%
Pfizer	25.000,00	5,48%
H. Lundbeck	25.000,00	5,48%
Stichting Buro ECNP (European College of Neuropsychopharmacology)	7.500,00	1,64%
Total Industry	368.164,00	80,72%
Non Industry		
Universiteit Maastricht	31.382,81	6,88%
Asbl Oeuvres des Frères de la Charité CNP Saint-Martin	5.000,00	1,10%
University of Munster	20.957,00	4,59%
Odense University Hospital	14.393,00	3,16%
EPF - European Patients Forum	2.760,00	0,61%
ECNP - European College of Neuropsychopharmacology	2.000,00	0,44%
EBC - European Brain Council	1.235,60	0,27%
Membership	9.725,00	2,13%
Other Donations	500,00	0,11%
Total Non Industry	87.953,80	19,28%

January - December 2022		
Operating income 2022	456.117,80	100,00%
Controle	-456.117,80	
	0,00	



GAMIAN-Europe
The Voice of Patients in Mental Health
www.gamian.eu
Rue du Trone 60 - 1050
Ixelles, Belgium